Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
Alzamend Neuro, Inc. (NASDAQ:ALZN) made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check.
周二，Alzamend Neuro, Inc.（纳斯达克股票代码：ALZN）宣布决定终止其 “市场” 股票发行计划，引起了轰动。上次检查时股价下跌了近12％。
What To Know: The move, aimed at minimizing uncertainty and preserving shareholder value, saw Alzamend cease further sales of common stock under its at-the-market equity offering, effectively concluding its obligations related to the program. Despite initiating the termination process ten days prior, the official cessation is scheduled for May 16, 2024.
须知：此举旨在最大限度地减少不确定性并保持股东价值，使Alzamend停止了在市面股票发行下进一步出售普通股，实际上履行了与该计划相关的义务。尽管在十天前启动了终止程序，但正式停火定于2024年5月16日。
During the tenure of the offering program, Alzamend managed to sell approximately 1,076,821 shares of common stock, generating gross proceeds of around $1.3 million, translating to roughly $1.20 per share.
在发行计划期间，Alzamend设法出售了约1,076,821股普通股，总收益约为130万美元，相当于每股约1.20美元。
Alzamend Neuro said its focus on advancing treatments for Alzheimer's, bipolar disorder, major depressive disorder and post-traumatic stress disorder remains unwavering. Anchored by innovative therapeutic candidates like AL001 and ALZN002, licensed from the University of South Florida Research Foundation, Alzamend said it plans to continue its mission to bring safe and effective treatments to market rapidly.
Alzamend Neuro表示，其对推进阿尔茨海默氏症、躁郁症、重度抑郁症和创伤后应激障碍治疗的重点仍然坚定不移。Alzamend表示，在获得南佛罗里达大学研究基金会许可的 AL001 和 ALZN002 等创新候选疗法的支持下，它计划继续其使命，将安全有效的疗法迅速推向市场。
The market reacted swiftly to the new developments, with Alzamend Neuro shares trading lower following the termination of the equity offering program. This strategic move underscores Alzamend's commitment to navigating challenges and maintaining shareholder confidence amid evolving market dynamics.
市场对新的事态发展迅速做出了反应，股票发行计划终止后，Alzamend Neuro的股价走低。这一战略举措凸显了Alzamend致力于在不断变化的市场动态中应对挑战和保持股东信心的承诺。
ALZN Price Action: Alzamend Neuro shares were down 11.9% at 62 cents Tuesday afternoon, according to Benzinga Pro.
ALZN价格走势：根据Benzinga Pro的数据，周二下午Alzamend Neuro股价下跌11.9％，至62美分。
Image: courtesy of Alzamend Neuro.
图片：由 Alzamend Neuro 提供。
译文内容由第三方软件翻译。